DANBURY, Conn., Oct. 5, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced it will be hosting a meeting for analysts and investors on October 11, 2012 in New York. During the meeting, independent experts in the field of diabetes will provide an overview of the unmet medical needs and review the therapeutics in development as they relate to Biodel's major programs. Biodel's senior management will review the company's pipeline in areas of ultra-rapid-acting insulin, glucagon and other aspects of the business.
Lutz Heinemann, PhD, Founder, former CEO and Scientific Advisor Profil Institute for Metabolic Research will present the limitations of current meal-time insulins and what the future holds. Donna Rice, MBA, BSN, RN, CDE, FAADE, President of Big Picture Health and former President of the Diabetes Health and Wellness Institute (affiliate of Baylor Health Care Systems) will discuss hypoglycemia and using glucagon in clinical practice. Steven Russell, MD, PhD, Investigator at the Massachusetts General Hospital Diabetes Research Center in Boston, MA and Assistant Professor of Medicine at Harvard Medical School will be joined by Edward Damiano, PhD, Associate Professor of Biomedical Engineering at Boston University to describe the coming of age of the bionic endocrine pancreas. Biodel's senior management will review the company's product candidates being developed to address the issues described by the independent experts.
The presentations will be webcast live through the "Investors" section of the company's website beginning at 8:30 a.m. Eastern Time. To access the webcast, please log on to Biodel's website at www.biodel.com approximately fifteen minutes prior to the presentation to register and download any necessary audio software. A recording will be made available on the website for 90 days following the event.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their
Safe-Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates. Forward-looking statements represent our management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the success of our product candidates, particularly our proprietary formulations of injectable insulin that are designed to be absorbed more rapidly than the "rapid-acting" mealtime insulin analogs presently used to treat patients with Type 1 and Type 2 diabetes and our liquid formulation of glucagon that is intended to treat patients experiencing severe hypoglycemia; our ability to successfully complete a Phase 2 clinical trial of a proprietary insulin formulation in a timely manner, and the outcome of that trial; our ability to conduct pivotal clinical trials, other tests or analyses required by the U.S. Food and Drug Administration, or FDA, to secure approval to commercialize a proprietary formulation of injectable insulin or a liquid formulation of glucagon; the success of our formulation development work with insulin analog-based formulations of a proprietary injectable insulin and a liquid formulation of glucagon; our ability to secure approval from the FDA for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; the progress, timing or success of our research, development and clinical programs, including any resulting data analyses; our ability to develop and commercialize a proprietary formulation of injectable insulin that may be associated with less injection site discomfort than Linjeta™ (formerly referred to as VIAject®), which is the subject of a complete response letter we received from the FDA; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of any such collaborations into which we enter, or our ability to commercialize our product candidates ourselves; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; the degree of clinical utility of our product candidates; the ability of our major suppliers to produce our products in our final dosage form; our commercialization, marketing and manufacturing capabilities and strategies; our ability to accurately estimate anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent report on Form 10-Q for the quarter ended June 30, 2012. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.
BIOD-G
CONTACT: Seth D. Lewis, +1-646-378-2952
Source: Biodel Inc.
News Provided by Acquire Media
SOURCE Biodel Inc.